51. 全身性強皮症 Scleroderma Clinical trials / Disease details

臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

273 trials found

diseases per page:

Showing 1 to 10 of 273 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04356287 (ClinicalTrials.gov)	April 2022	15/4/2020	Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis	Phase I/II Randomized Controlled Trial of Umbilical Cord-derived mesenChymAl stRomal cElls in System ...	Sclerosis, Systemic;Mesenchymal Stem Cells	Biological: UCMSC;Other: Placebo	Marie Hudson, MD	Assistance Publique - Hôpitaux de Paris;University Paris 7 - Denis Diderot;Université de Montréal;Me ...	Not yet recruiting	18 Years	N/A	All	18	Phase 1/Phase 2	NULL
2	NCT05198557 (ClinicalTrials.gov)	March 2022	6/1/2022	A Study of MT-0551 in Patients With Systemic Sclerosis	Phase 3 Study of MT-0551 in Patients With Systemic Sclerosis (Placebo-Controlled Double-Blind Study) ...	Systemic Sclerosis	Drug: Inebilizumab;Drug: Placebo	Mitsubishi Tanabe Pharma Corporation	NULL	Not yet recruiting	20 Years	80 Years	All	80	Phase 3	Japan
3	NCT05270668 (ClinicalTrials.gov)	February 22, 2022	27/2/2022	Phase 2 Safety and Efficacy Study of PRA023 in Subjects With Systemic Sclerosis Associated With Inte ...	A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 i ...	Diffuse Cutaneous Systemic Sclerosis;Interstitial Lung Disease	Drug: PRA023 IV;Device: Companion diagnostic ( CDx);Drug: Placebo	Prometheus Biosciences, Inc.	PPD	Recruiting	18 Years	N/A	All	100	Phase 2	United States
4	JPRN-jRCT2031210521	15/02/2022	26/12/2021	Phase 3 Study of MT-0551 in Patients with Systemic Sclerosis	Phase 3 Study of MT-0551 in Patients with Systemic Sclerosis (Placebo-Controlled Double-Blind Study) ...	Systemic Sclerosis	(1)MT-0551 group Participants will receive intravenous (IV) inebilizumabon Day 1 and Day 15 of rando ...	Kondou Kazuoki	NULL	Pending	>= 20age old	<= 80age old	Both	80	Phase 3	Japan
5	EUCTR2020-005764-62-PL (EUCTR)	31/01/2022	05/01/2022	A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients w ...	A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Effic ...	Diffuse Cutaneous Systemic Sclerosis MedDRA version: 21.0;Level: LLT;Classification code 10042953;Te ...	Product Code: HZN-825 INN or Proposed INN: HZN-825	Horizon Therapeutics Ireland DAC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	United States;Portugal;Greece;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Hungary;M ...
6	EUCTR2020-005764-62-NL (EUCTR)	31/01/2022	25/11/2021	A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients w ...	A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Effic ...	Diffuse Cutaneous Systemic Sclerosis MedDRA version: 21.0;Level: LLT;Classification code 10042953;Te ...	Product Code: HZN-825 INN or Proposed INN: HZN-825	Horizon Therapeutics Ireland DAC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	United States;Portugal;Greece;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Hungary;M ...
7	EUCTR2021-000230-33-IT (EUCTR)	26/01/2022	17/08/2021	TRIAL EVALUATING EFFICACY AND SAFETY OF HYDROXYCHLOROQUINE VERSUS PLACEBOIN EARLY SYSTEMIC SCLEROSIS ...	A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADD-ON TRIAL EVALUATING EFFICACY AND SAFETY OF HYDRO ...	Systemic Sclerosis (SSc) is a rare and orphan disease (DPCM 12 gennaio 2017-GU SG n°65-S.O. n°15 - 1 ...	Product Name: Idrossiclorochina solfato Product Code: [N/A] INN or Proposed INN: idrossiclorochina sol ...	UMBERTO I - POLICLINICO DI ROMA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	151	Phase 3	Italy
8	NCT04789850 (ClinicalTrials.gov)	January 2022	10/2/2021	Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis	Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis: a Phase II, Randomized, Control ...	Systemic Sclerosis	Drug: Itacitinib;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	18 Years	N/A	All	74	Phase 2	France
9	NCT04478994 (ClinicalTrials.gov)	November 17, 2021	16/7/2020	A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)	A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safet ...	Diffuse Cutaneous Systemic Sclerosis	Biological: TEPEZZA;Other: Placebo	Horizon Therapeutics USA, Inc.	NULL	Recruiting	18 Years	80 Years	All	25	Phase 1	United States
10	NCT04915950 (ClinicalTrials.gov)	November 3, 2021	1/6/2021	A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Ray ...	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the ...	Raynaud's Phenomenon Secondary to Systemic Sclerosis	Drug: Temanogrel;Drug: Placebo	Arena Pharmaceuticals	NULL	Recruiting	18 Years	75 Years	All	48	Phase 2	United States;United Kingdom

First Previous1 2 3 4 5…28Next Last